Cybereason vs Recursion
Side-by-side comparison to help you choose the best tool.
Cybereason
paidAI endpoint detection and response platform that constructs full attack stories from individual alerts to reduce investigation time for security analysts. The MalOp (Malicious Operation) engine correlates thousands of events into a single attack narrative showing the full scope of an attack. Cybereason enables analysts to understand and respond to complex attacks in minutes rather than hours.
Recursion
paidRecursion is a clinical-stage biotechnology company using AI to industrialise drug discovery. It combines large biological image datasets with ML to identify disease-biology relationships and predict therapeutic candidates. Recursion's platform has generated one of the largest proprietary biological datasets in existence, enabling AI-driven target identification and compound screening at new scale.
| Feature | Cybereason | Recursion |
|---|---|---|
| Pricing | paid | paid |
| Category | Data & Analytics | Data & Analytics |
| Rating | 4.3 | 4.4 |
| Best For | Security analysts needing complete attack context to investigate and respond to complex threats | Pharmaceutical partners seeking AI drug discovery collaboration with one of the world's leading clinical-stage AI biotech companies |
| Views | 4 | 4 |
Pros
- Unique attack storyline reduces investigation complexity
- Strong correlation across multiple data sources
- Effective for detecting multi-stage attacks
Cons
- Interface can be overwhelming for new analysts
- Pricing is not transparent without sales engagement
Pros
- Pioneer in AI-driven drug discovery at scale
- Proprietary dataset is a competitive moat
- Active clinical programmes validate the approach
Cons
- Pharmaceutical industry-specific
- Platform not publicly available
- MalOp attack story engine
- AI-driven alert correlation
- Endpoint detection and response
- Threat hunting capabilities
- Automated remediation workflows
- AI-powered target identification
- Large-scale biological image analysis
- ML compound screening
- Disease-biology mapping
- Partnership programs